Lack of correlations between plasma concentration of medroxyprogesterone acetate, hypothalamic-pituitary function, and tumour response in patients with advanced breast cancer
- 1 March 1985
- journal article
- Published by Springer Nature in Cancer Chemotherapy and Pharmacology
- Vol. 14 (2) , 112-115
- https://doi.org/10.1007/bf00434347
Abstract
No abstract availableKeywords
This publication has 15 references indexed in Scilit:
- ADVANCED BREAST CANCER: RESPONSE TO HIGH DOSE ORAL MEDROXYPROGESTERONE ACETATEAustralian and New Zealand Journal of Medicine, 1984
- Medroxyprogesterone acetate (MAP) plasma levels after multiple high-dose administration in advanced cancer patientsCancer Chemotherapy and Pharmacology, 1983
- Medroxyprogesterone acetate improvement of the hepatic drug-metabolizing enzyme system in rats after chemical liver injuryBiochemical Pharmacology, 1983
- Pharmacokinetic approach to the selection of dose schedules for medroxyprogesterone acetate in clinical oncologyCancer Chemotherapy and Pharmacology, 1982
- The pharmacokinetics of high-dose medroxyprogesterone acetate (MPA) in the therapy of advanced breast cancerCancer Chemotherapy and Pharmacology, 1982
- Comparative pharmacokinetics of medroxyprogesterone acetate administered by oral and intramuscular routesCancer Chemotherapy and Pharmacology, 1980
- High-dose medroxyprogesterone acetate in breast cancer resistant to endocrine and cytotoxic therapyCancer Chemotherapy and Pharmacology, 1979
- Assessment of response to therapy in advanced breast cancerPublished by Elsevier ,1978
- A radioimmunoassay for serum medroxyprogesterone acetateThe Journal of Steroid Biochemistry and Molecular Biology, 1978
- Progestin therapy of breast cancer: comparison of agents.BMJ, 1967